Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 22Leukemia 18Lymphoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 7Lymphoma, B-Cell, Marginal Zone 7Lymphoma, Non-Hodgkin 6Hodgkin Disease 6Graft vs Host Disease 6Myelodysplastic Syndromes 5Leukemia, Myeloid, Acute 5Lymphoma, Mantle-Cell 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Waldenstrom Macroglobulinemia 3Multiple Myeloma 3Hematologic Neoplasms 3Carcinoma, Renal Cell 3Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Mycosis Fungoides 2Lymphoma, T-Cell, Peripheral 2Lymphoma, B-Cell 2Leukemia, Myelomonocytic, Chronic 2Kidney Neoplasms 2Bronchiolitis Obliterans Syndrome 2Blast Crisis 2Thrombocythemia, Essential 1Stomach Neoplasms 1Sezary Syndrome 1

Interventions

Cyclophosphamide 22blinatumomab 18Cytarabine 15fludarabine 13Azacitidine 12venetoclax 10fludarabine phosphate 10Rituximab 8Lenalidomide 7Dexamethasone 7Methotrexate 6Daunorubicin 6Mercaptopurine 5daratumumab 4Whole-Body Irradiation 4Vincristine 4Melphalan 4Idarubicin 4Etoposide 4Busulfan 4pembrolizumab 3obinutuzumab 3Radiotherapy 3Maintenance 3Immunotherapy, Adoptive 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Drug Therapy 3Cladribine 3Asparaginase 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm, Residual × Pentostatin × Clear all
NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
69 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡